| Previous close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 55.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.0200 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Financial Times
Reversal of fortunes for Covid-19 vaccine winners
At the height of the pandemic, investors clamoured to buy vaccine makers, the closest thing to a sure bet. Shares in Pfizer, which developed a vaccine and an antiviral, have plummeted 46 per cent from their peak in late 2021, while its German vaccine partner BioNTech is down 75 per cent and rival Moderna has plunged 79 per cent. Less successful vaccine makers have fallen back even more dramatically: shares in Novavax, which has an approved Covid-19 shot that has sold far fewer than the mRNA jabs, has fallen 97 per cent since early 2021.
Motley Fool3 Top Stocks to Buy in October and Hold Forever
Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity.
ZacksBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.
